|
Effect on health-related quality of life (HRQOL) of adjuvant treatment (tx) with dabrafenib plus trametinib (D + T) in patients (pts) with resected stage III BRAF-mutant melanoma. |
|
|
Honoraria - 4SC; Agenus; Amgen; Array BioPharma; AstraZeneca; Bristol-Myers Squibb; Grunenthal; Immunocore; Incyte; LEO Pharma; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sysmex |
Consulting or Advisory Role - 4SC; Amgen; Bristol-Myers Squibb; Immunocore; Incyte; Merck Serono; Merck Sharp & Dohme; Mologen; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Incyte; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Serono; Novartis; Roche/Genentech |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche |
Research Funding - Amgen; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; Merck Serono; Merck Sharp & Dohme; Novartis; Roche |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MedImmune; Merck Serono; Merck Sharp & Dohme; Nektar; Novartis; OncoSec; Philogen; Provectus; Regeneron; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Roche/Genentech |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; Novartis |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra |
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; EUSA Pharma; GlaxoSmithKline; MSD; Novartis; Pfizer; Pierre Fabre; Roche/Genentech; Sectra |
Research Funding - Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pfizer; Roche/Genentech |
|
|
Consulting or Advisory Role - Incyte (Inst) |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Merck Serono; Merck Serono (Inst); MSD; MSD (Inst); Novartis; Novartis (Inst); Roche; Roche (Inst) |
|
|
Consulting or Advisory Role - Novartis |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novartis; Roche |
|
|
Honoraria - Bristol-Myers Squibb; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
|
|
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
Honoraria - Bristol-Myers Squibb; Merck; Novartis |
Consulting or Advisory Role - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Roche (Inst); TEVA (Inst) |
Speakers' Bureau - GlaxoSmithKline; Merck |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma; Takeda |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst) |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Immunocore; Merck; Novartis; Roche |
Research Funding - Merck (Inst); Prometheus (Inst) |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche |
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech |